Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Baxter
Medtronic

Last Updated: January 21, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for CUDC-907


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug CUDC-907?

CUDC-907 is an investigational drug.

There have been 13 clinical trials for CUDC-907. The most recent clinical trial was a Phase 2 trial, which was initiated on December 22nd 2016.

The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Head and Neck Neoplasms. The leading clinical trial sponsors are Curis, Inc., National Cancer Institute (NCI), and The Leukemia and Lymphoma Society.

There are one hundred and seventy-five US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for CUDC-907
TitleSponsorPhase
Fimepinostat in Treating Brain Tumors in Children and Young AdultsCannonball Kids' Cancer FoundationEarly Phase 1
Fimepinostat in Treating Brain Tumors in Children and Young AdultsCuris, Inc.Early Phase 1
Fimepinostat in Treating Brain Tumors in Children and Young AdultsPacific Pediatric Neuro-Oncology ConsortiumEarly Phase 1

See all CUDC-907 clinical trials

Clinical Trial Summary for CUDC-907

Top disease conditions for CUDC-907
Top clinical trial sponsors for CUDC-907

See all CUDC-907 clinical trials

US Patents for CUDC-907

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CUDC-907 ⤷  Try it Free Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE) ⤷  Try it Free
CUDC-907 ⤷  Try it Free Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) ⤷  Try it Free
CUDC-907 ⤷  Try it Free Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) ⤷  Try it Free
CUDC-907 ⤷  Try it Free Aerosol pirfenidone and pyridone analog compounds and uses thereof AVALYN PHARMA INC. (Seattle, CA) ⤷  Try it Free
CUDC-907 ⤷  Try it Free Heterocyclic estrogen receptor modulators and uses thereof Genentech, Inc. (South San Francisco, CA) ⤷  Try it Free
CUDC-907 ⤷  Try it Free Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers Immunomedics, Inc. (Morris Plains, NJ) ⤷  Try it Free
CUDC-907 ⤷  Try it Free Compounds and combinations for the treatment of HIV Gilead Sciences, Inc. (Foster City, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CUDC-907

Drugname Country Document Number Estimated Expiration Related US Patent
CUDC-907 Argentina AR107432 2036-01-11 ⤷  Try it Free
CUDC-907 Australia AU2017207268 2036-01-11 ⤷  Try it Free
CUDC-907 Australia AU2019203280 2036-01-11 ⤷  Try it Free
CUDC-907 Australia AU2021201018 2036-01-11 ⤷  Try it Free
CUDC-907 Brazil BR112018014015 2036-01-11 ⤷  Try it Free
CUDC-907 Canada CA3010509 2036-01-11 ⤷  Try it Free
CUDC-907 China CN108473471 2036-01-11 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.